For those still in GH

I saw this article in Science Daily noting Dana Farber Institute research.

A new blood test in development has shown ability to screen for numerous types of cancer with a high degree of accuracy, a trial of the test shows…The overall specificity was 99.4%, meaning only 0.6% of the results incorrectly indicated that cancer was present.

The test looks for chemical tags in DNA that influence gene activity. It looks for DNA shed by cancer cells into the bloodstream when they die. The test does a reasonably good job pf identifying the tissue or organ of origin. Seems like it would be significant competition for GH, although I am far from knowledgeable about the science behind these approaches. More at:…

For investors, The company behind the test GRAIL, Inc. looks to be privately funded at this point by some big names including Amazon, Bill Gates,Johnson & Johnson, Bristol-Myers Squibb and others.



I bought GH on the drop. Considering the adoption rate and the long term potential, this stock should be worth much more than $6B.